Mela Sciences secondary stock offering
This article was originally published in The Gray Sheet
Executive Summary
Developer of the MelaFind melanoma diagnostic system will gross $16.5 million from a secondary stock offering of 2.2 million shares that priced at $7.50 each on June 30. Mela Sciences expects the offering to close on July 6. The proceeds will help fund MelaFind commercialization efforts, the company says. FDA's General and Plastic Surgery Devices Panel will meet Aug. 26 to review a PMA application for the device, which was filed in June 2009 (1"The Gray Sheet" June 28, 2010). Underwriters for the stock offering include Needham & Company and Leerink Swann